The immune response against therapeutic clotting factors VIII and IX (FVIII and FIX) is a major adverse event that can effectively thwart their effectiveness in correcting bleeding disorders. inversions in the gene lead to severe haemophilia A. The first-line therapy for severe haemophilia is usually intravenous treatment with protein therapeutics to replace the deficient coagulation… Continue reading The immune response against therapeutic clotting factors VIII and IX (FVIII